FDA reversals on UniQure, Moderna approvals worry investors

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from…

Read More

Amazon says Anthropic remains available outside of defense work

Amazon said Friday it will continue offering Anthropic’s artificial intelligence technology to its cloud customers, excluding work involving the Department of Defense. The announcement comes after the federal agency informed Anthropic on Thursday that it would label the company a “supply chain risk.” Anthropic responded by saying it has “no choice” but to challenge the…

Read More